Brief: Senti Bio Announces FDA Clearance of IND Application for SENTI-202

Senti Biosciences Holdings

22/12/2023 11:51

Dec 22 (Reuters) - Senti Biosciences Inc  SNTI.O :
    * SENTI BIO ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR
SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY
HEMATOLOGIC MALIGNANCIES INCLUDING ACUTE MYELOID LEUKEMIA
    * SENTI BIOSCIENCES INC- INITIAL CLINICAL EFFICACY DATA
EXPECTED
BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025
    * SENTI BIOSCIENCES INC- FIRST PATIENT IN PHASE 1 CLINICAL
TRIAL
EXPECTED TO BE TREATED IN Q2 2024

Source text for Eikon:  ID:nGNX1Cn5nx 
Further company coverage:  SNTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))